Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing

Małgorzata Ostrowska 1, Jacek Kubica 1, Piotr Adamski 1, Aldona Kubica 2, Ceren Eyileten 3, Marek Postula 3, Aurel Toma 4, Christian Hengstenberg 4 and Jolanta M. Siller-Matula 3, 4*

1 Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland, 2 Department of Health Promotion, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland, 3 Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CEPT), Medical University of Warsaw, Warsaw, Poland, 4 Department of Cardiology, Medical University of Vienna, Vienna, Austria

Antiplatelet therapy with P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor, cangrelor) is a cornerstone of medical therapy after percutaneous coronary interventions. Significant prevalence of high on-treatment platelet reactivity (HTPR) on clopidogrel treatment led to introduction of more potent P2Y12 inhibitors: prasugrel (a third generation thienopyridine), ticagrelor, and cangrelor (cyclopentyl-triazolo-pyrimidines). Nevertheless, more potent platelet inhibition and resulting low on-treatment platelet reactivity (LTPR) has led to increased risk of major bleeding events. These limitations resulted in a need for an individualized antiplatelet therapy approach. This review discusses the current role and future perspectives of diagnostic tools such as platelet function testing to optimize antiplatelet therapy with a focus on deescalating therapies to reduce bleeding risks.

Keywords: P2Y12 inhibitors, antiplatelet therapy, ACS, HPR, LPR, precision medicine

ROLE OF PLATELETS IN ARTERIAL THROMBOSIS

Myocardial infarction (MI) is generally a consequence of unstable atherosclerotic plaque rupture or erosion, caused by endothelial damage (1). In patients with ST-segment elevation myocardial infarction (STEMI), the rupture of atherosclerotic plaque is associated with exposure of the lipid core and subendothelial collagen fibers, both of which initiate activation of platelets, and thrombus formation that usually lead to acute obstruction of the coronary artery (1). On the other hand, in patients with non-ST segment elevation myocardial infarction (NSTEMI) the MI is usually caused by a clot formed on unstable coronary plaque, which does not produce complete obstruction of the artery lumen (1). Excessive activation and aggregation of platelets play a pivotal role in the pathogenesis of both types of MI (2). Platelets are the smallest, anuclear morphotic elements of the blood, which derive from megakaryocytes and live 7–10 days. Their surface is covered with multiple receptors and their organelle include factors promoting the clot formation (Figure 1).

Platelets are responsible for the primary hemostasis, that consists of platelet adhesion, secretion, and aggregation (2). Vascular injury and exposure of the von Willebrand factor initiates platelets adhesion and activation, as a result the surface integrins α2β1 and α2bβ3 (also called GP IIb/IIIa) gain high affinity to collagen and fibrinogen (3, 4). One of the most powerful modulators of platelet function is ADP, the main agonist of platelet P2Y1 and P2Y12 receptors (5). Stimulation of the P2Y1 receptor results in phospholipase C activation (6, 7), while stimulation of the P2Y12
receptor deactivates adenyl cyclase resulting in termination of cyclic adenosine monophosphate production, translating into lack of inhibition of the phospholipase C (8). Stimulation of both P2Y receptors leads to hydrolysis of phosphatidylinositol by the activated phospholipase C to triphosphate inositol and diacylglycerol (3). Triphosphate inositol is responsible for opening of the membrane calcium channels and influx of calcium, which facilitates cytoskeleton modification and change of shape to spherical, transport of α granules and dense bodies to the central part and release of their components (6). The process of aggregation is based on bridging of two neighboring platelets with fibrinogen, via activated GP IIb/IIIa platelet membrane receptors, allowing formation of the primary clot (9). Further platelet activation initiates next phase of platelet aggregation associated with cyclooxygenase-1 mediated production of thromboxane A₂ from arachidonic acid. Thromboxane A₂ further promotes platelet aggregation and vasoconstriction (10). The next stage is secondary hemostasis, it is initiated by platelet products and mediated by coagulation factors (2). Undesired platelet activation, leading to clot formation inside the coronary arteries explains the pathomechanism of MI and stent thrombosis—a possibly lethal complication of percutaneous coronary intervention (PCI) with stent implantation (1, 11).

**ANTIPLATELET AGENTS**

Current armamentarium of antiplatelet agents includes four groups of drugs and is summarized in Table 1.

**Aspirin**

Aspirin represents the cornerstone of antithrombotic therapy. Aspirin is an irreversible antagonist of the cyclooxygenase-1, that blocks the production of the thromboxane A₂—one of the most powerful promoters of platelet aggregation (13). In patients with acute coronary syndrome (ACS), an initial oral loading dose of 150–300 mg of non-enteric coated formulation is recommended, followed by 75–100 mg once daily regimen (12, 14, 15). Life-long maintenance therapy with acetylsalicylic acid is indicated in all patients in secondary prevention of coronary artery disease (16). Although arachidonic acid induced platelet aggregation varies according to several variables (as age or sex), no routine monitoring of its treatment is required (15, 17). In case of aspirin intolerance, chronic clopidogrel therapy is recommended as an alternative (16).
TABLE 1 | Groups of antiplatelet agents.

| Group of antiplatelet agents | Receptor agonist | Drug/s | Route of administration | Mode of platelet inhibition | Current place in ACS treatment in ESC guidelines (12) |
|-----------------------------|-----------------|--------|-------------------------|-----------------------------|-------------------------------------------------|
| Cyclooxygenase-1 antagonist | -               | Acetylsalicylic acid | Oral/Intravenous        | Irreversible             | I A                                              |
| P2Y12 antagonists           | ADP             | Clopidogrel, Prasugrel, Ticagrelor, Cangrelor | Oral/Intravenous        | Irreversible             | I A                                              |
| GP IIb/IIIa antagonists      | Fibrinogen      | Abciximab, Tiroliban, Eptifibatide | Intra/venous            | Noncompetitive           | C                                                |
| PAR-1 antagonist             | Thrombin        | Vorapaxar | Oral/Intra/venous        | Competitive               | - -                                              |

*Level of evidence A in ST-elevation acute myocardial infarction, level of evidence B in non-ST-elevation acute coronary syndromes. ACS, acute coronary syndrome; ADP, adenosine diphosphate; ESC, European Society of Cardiology; PAR-1, protease-activated receptor 1.

P2Y12 Receptor Antagonists
Dual antiplatelet therapy, composed of an aspirin and an antagonist of the platelet P2Y12 receptor, is a foundation of modern ACS therapy. There are three types of purinergic receptors: P2X1, P2Y1, and P2Y12 on the platelet surface, but only the P2Y12 has become a target for antithrombotic therapies that is used in everyday clinical practice (17). ADP is an agonist of the P2Y12 receptors. It activates the P2Y12 receptor via stimulation of the Ga12 protein, which deactivates adeny cyclase translating into decreased cyclic adenosine monophosphate synthesis, which is responsible for phospholipase C inhibition, thus leading to platelet aggregation (8). Stimulation of the Ga12 protein by ADP activates also the GP IIb/IIIa receptor leading to induction of fibrinogen bridging, and initiation of the secretion of platelet derived products (18).

Contemporary armamentarium of the P2Y12 receptor inhibitors includes two thienopyridines: clopidogrel and prasugrel, and two non-thienopyridine drugs: ticagrelor and cangrelor (19). Thienopyridines are oral pro-drugs demanding hepatic activation via cytochrome P450, their metabolites irreversibly bind to the P2Y12 receptors for 7–10 days, which may impact the time to surgery after cessation (20). Whereas, both non-thienopyridines are potent, reversible and direct acting drugs, characterized by different route of administration—ticagrelor is administered orally, while cangrelor intravenously. Beside antiplatelet action, P2Y12 receptor inhibitors seem to exert a whole palette of pleiotropic effects including: increased adenosine plasma concentration in ticagrelor treated patients leading to increase in adenosine-related coronary blood flow, cardioprotection, promotion of the release of antiocoagulative factors (21). These off-platelet effects are also associated with dyspnea and bradycardia. Additional off-target effects include improvement in peripheral arterial function and endothelial function, plaque stabilization and post-conditioning mimetic effect with cangrelor observed in animal models (22). Basic characteristic of all four P2Y12 receptor antagonists is presented in Table 2.

European Society of Cardiology (ESC) guidelines clearly recommend in patients with ACS the use of more potent antiplatelet agents like ticagrelor and prasugrel, with loading doses (ticagrelor 180 mg, prasugrel 60 mg), followed by maintenance doses (ticagrelor 90 mg twice daily, prasugrel 10 mg once daily), limiting the use of clopidogrel to situations when newer agents are not available or contraindicated (600 mg loading dose, followed by 75 mg maintenance dose) (12, 14, 15). Ticagrelor can also be used in STEMI patients after fibrinolysis (23). Moreover, guidelines advise to consider the use of cangrelor in P2Y12 receptor inhibitor naïve patients and to continue the infusion for 2 h or until the end of PCI (12). Dual antithrombotic therapy post ACS shall be continued for up to 12 months, unless there are contraindications such as excessive risk of bleeding. Noteworthy, in high ischemic-risk patients, who have not suffered from bleeding, dual antiplatelet therapy with ticagrelor in reduced dose of 60 mg twice daily may be maintained beyond 1 year for up to 3 years (12). In patients with chronic coronary syndromes undergoing PCI, dual antithrombotic regimen composed of aspirin and clopidogrel remains the well-known standard of care, while ticagrelor or prasugrel use is limited to high-risk situations like previous stent thrombosis (16). In general, after elective stent implantation P2Y12 inhibitor should be continued for up to 6 months (12). Of note, in high bleeding risk patients with chronic coronary syndrome, dual antiplatelet therapy can be shortened to 1 month, while in those post ACS with high ischemic and low bleeding risk it may prolonged for up to 30 months (12, 16). A special population of interest represents patients who require combination of antiplatelet therapy and anticoagulation. Recently, it has been shown that among patients with atrial fibrillation and chronic coronary syndrome (>1-year after the index event), the addition of antiplatelet drugs, as a monotherapy or dual antiplatelet therapy, does not provide added protection against coronary events, but increases the risk of major bleeding (24).
Glycoprotein IIb/IIIa Receptor Antagonists

Another group of antithrombotic agents are inhibitors of the GP IIb/IIIa receptors. These glycoproteins belong to adhesion molecules and are the most abundant platelet surface receptors. Their role in platelet aggregation is pivotal, after activation, and change of conformation they gain high affinity for fibrinogen, von Willebrand factor and prothrombin (25). Fibrinogen molecule has binding sites on both sides allowing bridging between two neighboring platelets, thus initiating aggregation. In everyday clinical practice we use three intravenous GP IIb/IIIa inhibitors: abciximab, eptifibatide, and tirofiban. Beside potent antiplatelet effect they can exert some off-target actions, mainly anti-inflammatory (26). The use of GP IIb/IIIa antagonists should be reserved for bail-out situations, if there is evidence of no-reflow or a thrombotic complication (class of recommendation IIa, level of evidence C) (12). Their use in patients in whom coronary anatomy is not known is not recommended (class of recommendation III, level of evidence A) (12).

ASSESSMENT OF PLATELET INHIBITION UNDER ANTIPLATELET THERAPIES

Platelet Function Testing

Many different methods to assess platelet function exist, beginning with the historic golden standard—light transmission aggregometry, that measures the difference between light transmission through platelet rich plasma and platelet poor plasma, assessment of platelet aggregation on fibrinogen-coated microparticles (VerifyNow assay) or metal electrodes (Multiplate analyzer), measurement of the VASP protein phosphorylation (VASP assay), assessment of platelet aggregation in vitro in conditions similar to physiological blood flow (PFA-100, PFA-200, Innovance P2Y12, IMPACT-R), assessment of the clot strength (thromboelastography), measurement of the thrombocytes number before and after the addition of an agonist (Plateletworks) (27–29). It has to be acknowledged that due to great differences in assessment of platelet reactivity between available tests, a diagnosis of either HTPR or LTPR based on one method can be unconfirmed with the use of a different method. According to both American and European groups of experts there are three recommended platelet function tests: the VerifyNow assay, the Multiplate analyzer, and the VASP assay for clinical guidance (30, 31). In the HARMONIC study platelet reactivity values assessed with all three recommended platelet function tests in MI patients treated with ticagrelor correlated well with each other, however a significantly higher correlation was demonstrated between the VerifyNow and Multiplate tests than in other assay combinations (32). Interestingly, emerging concepts as platelet redox assessment (intracellular concentration of reactive oxygen species, activity of antioxidant enzymes, reduced/oxidized glutathione ratio, level of lipid peroxidation, Cu/Zn ratio, and molecular oxygen consumption) might be potentially useful to establish the platelet-related etiological factors in different disorders and to evaluate the antiplatelet therapies (33).

High On-Treatment Platelet Reactivity (HTPR)

Numerous studies have shown that up to 40% of patients exhibit HTPR under clopidogrel treatment (34–42). There are many potential causes of this phenomenon including clinical variables such as ACS at admission, diabetes mellitus, renal failure, drug-drug interactions, non-adherence to therapy, genetic polymorphism of genes coding cytochrome P450 enzymes (crucial in clopidogrel bioactivation) or glycoprotein P (responsible for clopidogrel absorption in intestines) (37, 43–48). Recently, an association between the circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) levels, HTPR and ischemic events in ACS patients undergoing PCI were described (49). There is a clear evidence showing that HTPR on clopidogrel is a significant risk factor for atherothrombotic events, including MI, stent thrombosis, cardiovascular death and cerebrovascular events (40, 50–52). There are some therapeutic options to overcome HTPR on clopidogrel. HTPR may also affect patients treated with newer, more potent antithrombotic agents such as prasugrel or ticagrelor, mainly within the first hours post loading dose in ACS patients undergoing PCI, when sufficient antiplatelet blockade is particularly desired (52–56). However,

| Chemical group | Clopidogrel | Prasugrel | Ticagrelor | Cangrelor |
|----------------|------------|-----------|------------|-----------|
| Prodrug (requiring hepatic activation) | Yes | No | No | No |
| Loading dose | 300/600 mg | 60 mg | 180 mg | 30 g/kg bolus |
| Maintenance dose | 75 mg | 10 mg | 2 x 90 mg | 4 g/kg/min infusion |
| Onset of action | 2–4 h | 30 min | 30 min | 2 min |
| Duration of antiplatelet effect | 3–10 days | 5–10 days | 3–4 days | 1–2 h |
| Excretion route | Renal and biliary | Renal and feces | Biliary | Renal and feces |
| Recommended stop of treatment before surgery | 5 days | 7 days | 3 days | 1 h |

TABLE 2 | Characteristics of P2Y12 receptor antagonists.
in a recently published systematic review and meta-analysis, early (>2 h pre-PCI) vs. late (<2 h pre-PCI or post-PCI) administration of loading doses of potent antiplatelet agents did not improve ischemic outcomes in more than 60,000 patients, questioning the importance of early loading (57). In contrast, early clopidogrel loading in ACS or STEMI patients reduced the risk of adverse events (57). The prevalence of HTPR in patients treated with ticagrelor was significantly lower as compared with those receiving prasugrel in a meta-analysis by Lemesle et al. (58). It was previously documented that age, gender, food, preloading with clopidogrel or genetic polymorphisms do not affect ticagrelor metabolism or its antplatelet effect (59–61). Diversely, morphine which used to be a golden standard of care for all patients presenting with acute MI, was found to attenuate ticagrelor bioavailability and its antplatelet action, mainly due to vomiting and decelerating the intestinal passage and absorption of ticagrelor (53, 62). There are few disputed strategies to overcome the morphine-ticagrelor interaction, either by crushing ticagrelor tablets, giving other analgesic, co-administering naloxone or metoclopramide (62–64). In a prospective, observational PINPOINT trial it has been found that ticagrelor concentration was reduced and antplatelet response was delayed in the initial hours of treatment in STEMI patients as compared with NSTEMI patients (65). In a subsequent analysis, it has been reported that the main determinants of HTPR at 1 and 2 h after ticagrelor loading dose are presence of STEMI and morphine co-administration (66). Furthermore, the presence of STEMI and diabetes mellitus were found to be associated with impaired metabolism of ticagrelor within first 6 h post ticagrelor loading dose in ACS patients (67). It has been recently published, that bioavailability of ticagrelor in MI patients managed with mild therapeutic hypothermia after out-of-hospital cardiac arrest is significantly decreased, thus increasing the risk of stent thrombosis, a possibly lethal complication, which is not uncommon in this specific subset of patients (68, 69). The main reasons of insufficient antplatelet effect of the P2Y12 inhibitors in out-of-hospital cardiac arrest survivors treated with mild therapeutic hypothermia are probably impaired gastrointestinal absorption and altered cytochrome activity causing a delay in drug metabolism (69–71). The temporary use of canagrelor may be a solution to overcome HTPR while oral antplatelet agents start to work in resuscitated patients undergoing mild therapeutic hypothermia (72). A single dose of intravenous morphine in STEMI patients was associated with a delay in the onset of prasugrel action (73), 65% of critically ill patients display HTPR on prasugrel, mainly due to poor absorption from gastrointestinal tract, as well as increased platelet reactivity induced by generalized inflammation (74).

### Conclusion of the Chapter

1. HTPR is a significant and modifiable risk factor for cardiac ischemic events and it is present frequently in clopidogrel treated patients.

2. Patients treated with prasugrel and ticagrelor can display HTPR mainly in the acute phase of treatment, which can be in part related to opioid use.

3. The routine use of platelet function testing to detect HTPR and undertake action is not recommended by the ESC guidelines. Nevertheless, HTPR should be taken into account, if de-escalation is undertaken from potent P2Y12 inhibitors to clopidogrel (12).

4. HTPR can be detected by a variety of platelet reactivity testing.

### Low On-Treatment Platelet Reactivity (LTPR)

With the introduction of more potent antplatelet agents the problem of LTPR associated with elevated bleeding risk became a major concern. In the TRITON-TIMI 38 trial the use of prasugrel as compared with clopidogrel was associated with significant increase of non-coronary artery bypass grafting related major bleeding, as well as life-threatening bleeding and bleeding leading to death according to the Thrombolysis in Myocardial Infarction (TIMI) criteria (75). While in the PLATO trial the administration of ticagrelor as compared with clopidogrel carried similar risk of major bleeding according to the PLATO trial criteria. However non-coronary artery bypass grafting related major bleeding and both major and minor bleeding occurred more frequently in the ticagrelor group (76).

Data on LTPR and bleeding on clopidogrel therapy comes from few small studies adapting different bleeding scales. Another limitation is low amount of serious bleeding events in those trials and predominant inclusion of low risk stable patients. First study reporting a link between LTPR and bleeding was conducted in 597 ACS patients treated with clopidogrel (77). In a 1-month observation period there were 16 bleeding episodes (5 serious and 11 small). Patients suffering from bleeding events were characterized by stronger platelet inhibition measured with the light transmission aggregometry (a previous golden standard) or the VASP assay. In a study by Sibbing et al. LTPR on clopidogrel (the cut-off value was based on the ROC curve analysis accounting 18.8 U according to the Multiplate analyzer) affected 39% of 2,533 patients with stable coronary artery disease undergoing PCI. Furthermore, those with LTPR had significantly higher risk of major in-hospital bleeding according to the TIMI criteria (78). Another study including 246 stable coronary artery disease patients receiving clopidogrel showed a relationship between >50% platelet inhibition measured with the light transmission aggregometry and occurrence of any bleeding event assessed with the use of very liberal bleeding scale called the BleedScore: 88% of all included bleeding events were superficial bleeds (79). Importantly, older age and female sex are important predictors of LTPR and of bleeding odds (80, 81).

There are few prospective studies providing a head-to-head comparison of platelet reactivity and bleeding risk in patients on prasugrel vs. ticagrelor (55, 82, 83). The first randomized trial included only 96 ACS patients treated with PCI (82). The half of them received ticagrelor, the other half received prasugrel, and platelet reactivity measurements were performed after 1 month. LTPR was defined as PRI≤20% in the VASP assay and occurred in 58% of ticagrelor recipients and 33% of prasugrel recipients with a lack of relationship between LTPR
and bleeding events. Another prospective registry including 512 patients with ACS treated with PCI (278 on ticagrelor, 234 on prasugrel) has shown that patients treated with ticagrelor were characterized by lower platelet reactivity assessed with the use of the VerifyNow device at 1 month post PCI, as compared with prasugrel (33.3 Platelet Reactivity Units (PRU) vs. 84.6 PRU; \( p < 0.001 \)) (83). Grade I Bleeding Academic Research Consortium (BARC) bleeding events were more frequent in the ticagrelor arm, while grade \( \geq 2 \) BARC bleeding events rate was similar irrespective of antiplatelet agent used. Another observational study assessing the relationship between occurrence of clinical events and platelet reactivity in 226 ACS patients (105 on ticagrelor and 121 on prasugrel) (55) indicated that bleeding episodes occurred in patients with platelet reactivity values \( \leq 23 \) U as assessed with the Multiplate Analyzer.

**Conclusion of the Chapter**

i) Due to the widespread use of potent P2Y\(_{12} \) inhibitors, the LTPR phenotype is frequent.

ii) LTPR is a well-documented risk factor for bleeding complications. Platelet function guided dose-adjustment of potent P2Y\(_{12} \) inhibitors may be a potential solution in patients who are presenting with a bleeding event (12).

**Therapeutic Window Strategy**

Based on the growing body of evidence showing an association between HTPR and ischemic events, and LTPR with bleeding events, the therapeutic window hypothesis was developed. It suggests that patients with platelet reactivity values within the middle range achieve the best net clinical benefit (28, 84). According to the European group of experts, the cut-off values for HTPR are as following: the VerifyNow assay >208 PRU, the Multiplate analyzer >46 Units (U) and the VASP assay >50% Platelet Reactivity Index (PRI) (31). The cut-off values for LTPR are as following: the VerifyNow assay <95 PRU, the Multiplate analyzer <19 U and the VASP assay <16% PRI.

**Conclusion of the Chapter**

i) The therapeutic window strategy to guide antiplatelet therapy might be an attractive strategy to improve patients net clinical benefit in terms of precision medicine.

ii) Clinical randomized trials aiming to answer that question are missing yet.

**STUDIES INVESTIGATING INDIVIDUALIZED ANTIPLATELET TREATMENT TO OVERCOME HTPR (TABLE 3)**

First small randomized trials comparing individualized antiplatelet therapy vs. standard of care antithrombotic treatment showed favorable results of antithrombotic adjusted therapy with either higher clopidogrel dose or addition of GP IIb/IIIa antagonist (104, 106, 107, 110, 113, 114). First large randomized trial that has brought huge disappointment to advocates of the individualized approach was the Gauging Responsiveness with a VerifyNow assay, Impact on Thrombosis and Safety (GRAVITAS) trial showing no benefit of administration of higher clopidogrel dose vs. standard clopidogrel dosing in 2200 low-to-moderate cardiovascular risk patients undergoing PCI with HTPR on-clopidogrel when it comes to death from cardiovascular causes, MI or stent thrombosis (hazard ratio [HR] 1.01; 95% confidence interval [CI] 0.58–1.76; \( P = 0.97 \)) in a 6 month follow-up (96). The next negative, similar size study—The Assessment by a Double Randomization of a Conventional Antiplatelet Strategy for Drug-Eluting Stent Implantation and of Treatment Interruption vs. Continuation 1 Year after Stenting (ARCTIC) trial demonstrated that the addition of acetylsalicylic acid, clopidogrel or switch to prasugrel as compared with conventional approach did not show any significant differences in the occurrence of the primary end point composed of death from cardiovascular causes, MI, stent thrombosis, urgent revascularization or stroke (HR 1.13; 95% CI 0.98–1.29; \( P = 0.10 \)) 1 year after stent implantation in a group of 2,440 low-to-moderate cardiovascular risk patients (95). The third large trial that was prematurely ended and almost entombed the individualized approach was The Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy with Prasugrel (TRIGGER-PCI). Trial included only 423 low cardiovascular risk patients with stable coronary artery disease undergoing elective PCI, and the strategy of switch from clopidogrel to prasugrel in those with HTPR on-clopidogrel did not bring reduction in the primary endpoint composed of death from cardiovascular causes and MI with concomitant increase in TIMI major bleeding at 6 months (94).

More promising results on the conception of individualized approach were shown by some prospective registries (89, 90, 92). The MADONNA registry, which included 798 patients (more than one third of them had MI), has shown that the non-guided group had significantly higher risk of stent thrombosis (odds ratio [OR] 7.9; 95% CI 1.08–69.2; \( P = 0.048 \)) at 30 days as compared with individualized therapy group (92). In the IDEAL-PCI registry the main strategy to overcome HTPR was a switch to a more potent antithrombotic agent (mainly prasugrel). At 30 days, there was only one definite stent thrombosis in the non-guided group (90). In the PECS registry, including only ACS patients, those with HTPR received either higher clopidogrel dose or prasugrel, while those below HTPR threshold received conventional clopidogrel therapy (89). The primary endpoint composed of all-cause death, MI, stent thrombosis or stroke at 1 year occurred more frequently in patients treated with higher clopidogrel doses than in conventional treatment group (HR 2.27; 95% CI 1.45–3.55; \( p < 0.0001 \)), while the risk of ischemic events in prasugrel recipients was similar to conventional treatment arm (HR 0.90; 95% CI 0.44–1.81; \( p = 0.76 \)). Worth adding is the fact that bleeding events (3/5 according to the BARC scale) were also more frequent in the higher clopidogrel dose group vs. conventional group (HR 2.09; 95% CI 1.05–4.17; \( p = 0.04 \)), while in prasugrel recipients it was similar to conventional treatment arm (HR: 1.90; 95% CI 1.17–3.08; \( p = 0.01 \)).
### TABLE 3 | Studies investigating individualized antiplatelet treatment.

| Study author/acronym   | Population       | n       | Follow-up | Outcome                          | Method          | Cut-off value                      | Study type                                                                 |
|------------------------|------------------|---------|-----------|----------------------------------|-----------------|------------------------------------|----------------------------------------------------------------------------|
| ELECTRA (85)           | MI               | 52      | 14 days   | Level of platelet inhibition     | VASP assay and MEA | 16% for LTPR, 50% for HTPR          | CRT: ticagrelor standard maintenance dose 2 × 90 mg vs. ticagrelor reduced maintenance dose 2 × 60 mg in patients 30 days post MI |
| TOPIC (86)             | PCI for ACS      | 646     | 1 year    | MACE, BARC ≥2 bleeding           | n/a             | n/a                                | CRT: continuation of ticagrelor/prasugrel vs. switch to clopidogrel in patients 1 month post ACS |
| TROPICAL-ACS (87)      | PCI for ACS      | 2,610   | 1 year    | Net clinical benefit/MACE or BARC ≥2 bleeding | MEA             | 46 U                               | CRT: guided de-escalation: 7 days prasugrel 5 or 10 mg + 7 days clopidogrel 75 mg after 14 days if HTPR prasugrel 5 or 10 mg, if no HTPR clopidogrel 75 mg vs. non-guided prasugrel 5 or 10 mg clopidogrel 75 mg |
| ANTARCTIC (88)         | PCI for ACS      | 877     | 1 year    | ST, MACE, BARC major bleeding    | VerifyNow       | 208PRU for HTPR 85 for LTPR        | CRT: guided: in case of HTPR on prasugrel 5 mg switch to prasugrel 10 mg, in case of LTPR on prasugrel 5 mg switch to clopidogrel 75 mg vs. non-guided prasugrel 5 mg |
| PECS REGISTRY (89)     | ACS+PCI          | 741     | 1 year    | ST, MACE, BARC major bleeding    | MEA             | 46 U                               | Observational: 600/150 mg clopidogrel vs. prasugrel in patients with HTPR |
| IDEAL-PCI (90)         | PCI              | 1,008   | 1 month   | ST                              | MEA             | 50 U                               | Observational: non-HTPR on clopidogrel arm vs. HTPR on clopidogrel individualized approach (reloading with clopidogrel, ticagrelor, or prasugrel; re-testing) |
| ISAR-HPR (91)          | PCI for CAD or ACS | 999    | 1 month   | ST, MACE, TIMI bleeding          | MEA             | 468AL/min                          | Retrospective HTPR on clopidogrel arm vs. prospective HTPR on clopidogrel individualized approach arm (reloading with clopidogrel, switch to prasugrel, re-testing) |
| MADONNA (92)           | PCI              | 798     | 1 month   | ST, MACE, TIMI major bleeding    | MEA             | 50 U                               | Non-randomized, controlled: non-guided vs. guided group (up to 4 loadings with 600 mg clopidogrel or 1 loading with prasugrel in patients with HTPR) |
| Kozinski et al. (93)   | ACS+PCI          | 71      | 1 month   | Level of platelet inhibition     | VASP assay      | 50%                                | Parallel-group, open-label study: patients with HTPR were assigned to prasugrel (30 mg loading dose, 10 mg maintenance dose) or clopidogrel (150 mg maintenance dose for 6 days and thereafter 75 mg maintenance dose) |
| TRIGGER-PCI (94)       | Elective PCI     | 423     | 6 months  | MACE, bleeding                   | VerifyNow       | 208PRU                             | CRT: prasugrel (loading of 60 mg and maintenance 10 mg) vs. clopidogrel (maintenance 75 mg) in patients with HTPR |
| ARCTIC (95)            | PCI with DES     | 2,440   | 1 year    | MACE                            | VerifyNow       | 235PRU                             | CRT: guided: clopidogrel (600 mg reloading and 75 mg or 150 mg maintenance) or prasugrel (60 mg loading and 10 mg maintenance) or GP IIb/IIIa inhibitors vs. non-guided: clopidogrel (maintenance 75 mg) in patients with HTPR |
| GAVRITAS (96)          | PCI for CAD or NSTE-ACS | 2,214  | 6 months  | MACE                            | VerifyNow       | 230PRU                             | CRT: 300/75 mg clopidogrel vs. 600/75 mg clopidogrel in patients with HTPR |
| Alexopoulos et al. (97)| CAD with clopidogrel treatment | 31 | 1 month | Level of platelet inhibition | VerifyNow       | 235PRU                             | Randomized, crossover: 10 mg prasugrel vs. 150 mg clopidogrel in patients with HTPR |
| Alexopolous et al. (98)| HD with clopidogrel treatment | 21 | 1 month | Level of platelet inhibition | VerifyNow       | 235PRU                             | Randomized, crossover: 10 mg prasugrel vs. 150 mg clopidogrel c |

(Continued)
| Study author/acronym | Population | n | Follow-up | Outcome | Method | Cut-off value | Study type |
|----------------------|------------|---|-----------|---------|--------|--------------|------------|
| Capranzano et al. (99) | Clopidogrel treatment + age >75 | 100 | Level of platelet inhibition | VerifyNow | 230PRU | Observational: prasugrel in patients with HTPR |
| Ferreiro et al. (100) | DMII | 30 | Level of platelet inhibition | VASP assay | 50% | Observational: clopidogrel vs. 150 mg clopidogrel in patients with HTPR |
| BOCLA Plan (101) | PCI | 504 | Level of platelet inhibition | IA | 5 Ω | Observational: 600/150 mg clopidogrel vs. ticlopidine vs. prasugrel in patients with HTPR |
| Gurbel et al. (102) | Stable CAD + previous PCI | 20 | 7 days | LTA | 43% | Observational: single dose elinogrel 60 mg in patients with HTPR |
| RESPOND (103) | Stable CAD + clopidogrel | 41 | 1 month | LTA | 43% | CRT crossover: ticagrelor 180/90 mg vs. clopidogrel 600/75 mg |
| Valgimigli et al. (104) | Elective PCI | 263 | In hospital | MACE | VerifyNow | 235PRU | CRT: tirofiban vs. placebo in patients with HTPR |
| ACCEL-RESISTANCE (105) | PCI | 60 | 1 month | Level of platelet inhibition | LTA | 50% | CRT: adjunctive clopidogrel vs. 150 mg clopidogrel in patients with HTPR |
| Bonello et al. (106) | PCI | 429 | 1 month | MACE, ST, bleeding | VASP assay | 50% | CRT: guided (repeated loading with clopidogrel 600 mg) vs. non-guided group |
| Bonello et al. (107) | PCI | 162 | 1 month | MACE | VASP assay | 50% | CRT: guided (repeated loading with clopidogrel 600 mg) vs. non-guided group |
| VASP-02 (108) | Elective PCI | 153 | 1 month | MACE, level of platelet inhibition | VASP assay | 69% | Observational: 150 mg clopidogrel in patients with HTPR |
| Trenk et al. (109) | Elective PCI | 117 | 14 days | Level of platelet inhibition | LTA | 14% | Observational: 150 mg clopidogrel vs. control in patients with HTPR |
| Cuisset et al. (110) | Elective PCI | 149 | 1 month | MACE | LTA | 70% | CRT: GP IIb/IIIa antagonists vs. control in patients with HTPR |
| Matezyk et al. (111) | MI | 200 | 10 weeks | Level of platelet inhibition | LTA | 80% | Observational: 600/150 mg clopidogrel in patients with HTPR |
| Neubauer et al. (112) | Elective PCI | 161 | Level of platelet inhibition | IA | 5 Ω | Observational: 600/150 mg clopidogrel vs. ticlopidine in patients with HTPR |

ACS, acute coronary syndrome; BARC, Bleeding Academic Research Consortium; CAD, coronary artery disease; CRT, controlled randomized trial; CYP, cytochrome P450; DM, diabetes mellitus; HD, haemodialysis; HTPR, high on-treatment platelet reactivity; IA, impedance aggregometry; LTA, light transmission aggregometry; LTPR, low on-treatment platelet reactivity; MACE, major adverse cardiovascular event; MEA, multiple electrode aggregometry; MI, myocardial infarction; n/a, not applicable; NSTE-ACS, non ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention; PRU, platelet reactivity unit; ST, stent thrombosis; TIMI, thrombolysis in myocardial infarction; U, unit; VASP, vasodilator stimulated phosphoprotein.
After failure of the first randomized trials investigating individualized antithrombotic therapy and some favorable data from registries, long-awaited results of the Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC) randomized study were recently published (88). The study was designed for elderly population including patients over 75 years old undergoing PCI for ACS. Participants were divided into two groups. In the monitoring group, patients received prasugrel 5 mg daily with dose or drug adjustment in case of HTPR, while in conventional group patients were treated with prasugrel 5 mg daily. Platelet function was tested with the VerifyNow assay. The cutoff values for HTPR and LTPR were based on the American consensus of experts, accounting ≥208 for ischemic events and ≤85 for bleeding events (30). The primary endpoint composed of cardiovascular death, myocardial infarction, stroke, stent thrombosis, urgent revascularization, and BARC-defined bleeding complications (types 2, 3, or 5) occurred in 120 (28%) patients in the monitoring group vs. 123 (28%) in the conventional group (HR 1.003, 95% CI 0.78–1.29; p = 0.98). Rates of bleeding events did not differ significantly between groups. Drug or dose adjustment based on platelet reactivity measurements did not improve the clinical outcome in a group of elderly patients undergoing PCI for ACS.

Conclusion of the Chapter

i) Trials on individualized antiplatelet approach had many limitations. These concerns are mainly due to the chosen low cardiovascular risk populations (mostly stable coronary disease patients), use of different cut-off points for HTPR, predominant use of higher clopidogrel doses instead of more potent antiplatelet agents to overcome HTPR, only single switch to other dose or antiplatelet agent, delayed time of randomization (after PCI or even day after PCI) and chosen compounds of the primary endpoint (34).

ii) Real life data from the registries showed more promising results.

STUDIES INVESTIGATING DE-ESCALATION OF ANTIPLATELET TREATMENT

TROPICAL

The randomized trial Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) assessed guided de-escalation of antiplatelet treatment in patients with MI treated with PCI in 2,610 patients (87). Investigators of the TROPICAL-ACS trial aimed to test safety and efficacy of antithrombotic treatment de-escalation from prasugrel in the acute phase of ACS to clopidogrel in the chronic phase based on platelet reactivity measured with the Multiplate analyzer. 1,304 patients were included to the de-escalation study arm. Participants were treated with prasugrel for a week, and then switched to clopidogrel for a week and after 14 days platelet reactivity assessment was performed resulting in either continuation of clopidogrel therapy or in case of HTPR switch back to prasugrel. In the conventional study arm, 1,306 patients were treated with prasugrel for 12 months. The primary endpoint was the net clinical benefit (cardiovascular death, MI, stroke or bleeding grade 2 or higher according to BARC criteria) and it occurred in 95 patients (7%) in the guided de-escalation group and in 118 patients (9%) in the control group (pnon—inferiority = 0.0004; HR 0.81; 95% CI 0.62–1.06; psuperiority = 0.12). Despite early de-escalation, there was no increase in the primary endpoint of ischemic events in the de-escalation group (32 patients [3%]) vs. the control group (42 patients [3%]; pnon—inferiority = 0.115), with similar frequency of BARC 2 or higher bleeding events in the de-escalation group vs. control group (64 [5%] vs. 79 [6%]; HR 0.82; 95% CI 0.59–1.13; p = 0.23). It is worth underlining that the trial was designed to test the non-inferiority hypothesis and the analysis was intention to treat. As a consequence, the platelet reactivity-guided antithrombotic drug de-escalation was non-inferior to recommended conventional 12 months prasugrel therapy at 1 year after PCI in MI patients in terms of the net clinical benefit.

TOPIC

In the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study, 645 patients 1 month after ACS were randomly assigned to either continuation of dual antiplatelet therapy composed of aspirin and potent antiplatelet agent or de-escalation to aspirin and clopidogrel (86). Drug de-escalation occurred without platelet function testing, however all patients underwent platelet reactivity assessment with the use the VASP assay at the time of randomization. The primary endpoint combining cardiovascular death, urgent revascularization, stroke and bleeding as defined as BARC ≥2 occurred in 85 (26.3%) patients in the unchanged drug group vs. 43 (13.4%) patients in the de-escalation group (HR 95%CI 0.48 (0.34–0.68; P < 0.01), with significant reduction in the occurrence of BARC ≥2 bleeding (48 [14.9%] vs. 13 [4%]; HR 95%CI 0.30 (0.18–0.50), P < 0.01). Additionally, the subanalysis revealed that at the time of randomization based on the results of platelet function testing, 47% of patients were classified with LTPR. Among this subpopulation, drug de-escalation brought the most prominent reduction in the primary endpoint incidence as compared with continued potent antiplatelet regimen (HR 0.29; 95% CI 0.17–0.51; p < 0.01). Nevertheless, the reduction of bleedings in the de-escalation group was mainly due to TIMI minimal and minor bleedings, with no difference in the major bleeding events.

ELECTRA

In the recently published Effectiveness of LowEir maintenance dose of TicagRelor early After myocardial infarction (ELECTRA) study, the antiplatelet efficacy of two ticagrelor maintenance dose regimens (reduced dose of 60 mg twice daily vs. standard dose of 90 mg twice daily) in stable patients at 30 days after acute MI were compared (85). The trial included 52 patients randomized in 1:1 ratio to the reduced or standard ticagrelor
maintenance dose. Platelet function testing with the use of the VASP assay and the Multiplate analyzer were performed 2 weeks after the treatment initiation. There were no significant differences in platelet reactivity between patients treated with reduced vs. standard ticagrelor dose (VASP: 10.4 [5.6–22.2] vs. 14.1 [9.4–22.1] %PRI; \( p = 0.30 \); Multiplate: 30.0 [24.0–39.0] vs. 26.5 [22.0–35.0] U; \( p = 0.26 \)). Importantly, the percentage of patients with HTPR was similar in reduced vs. standard ticagrelor dose (VASP: 4% vs. 8%; \( p = 0.67 \); Multiplate: 15% vs. 8%; \( p = 0.54 \)). In conclusion, the lower ticagrelor dose provided similar antiplatelet effect to the standard regimen.

Three observational registries aimed to assess the incidence of switching between P2Y\(_{12}\) receptor blockers:

**TRANSLATE-ACS**
The Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study in 8672 MI patients has reported that P2Y\(_{12}\) inhibitor switch occurred in 7.6% of participants (115). The switches were usually de-escalations from more potent agents to clopidogrel mainly due to economic reasons, while escalations from clopidogrel were mainly promoted by ischemic events.

**ATLANTIS-SWITCH**
The recently published, prospective, observational, multicenter ATLANTIS-SWITCH study included 571 ACS patients undergoing PCI treated with ticagrelor (45%) or prasugrel (55%) and investigated the frequency and predictors of either switch or drug discontinuation (116). The prevalence of P2Y\(_{12}\) antagonist stop was 5.9%, and of switch was 6.7% and it was more frequent in ticagrelor recipients as compared with prasugrel (15.9% vs. 9.2%; \( p = 0.016 \)). The majority of stop/switch choices were prompted by physicians (75%), they did not increase the risk of adverse cardiovascular events and were motivated by one of four identified independent predictors: major surgery, need for oral anticoagulation, TIMI major bleeding, or drug intolerance (116).

**SCOPE**
The SCOPE registry investigated the incidence of P2Y\(_{12}\) inhibitor switching in 1363 patients undergoing PCI (117). The P2Y\(_{12}\) inhibitor switch occurred in 10.5% and was not platelet function based. The authors concluded that de-escalation of antiplatelet treatment from more potent drugs to clopidogrel was an independent predictor of net cerebrovascular event (NACE) defined as a combination of adverse cardiovascular event and any bleeding event (OR 5.3; CI: 2.1–18.2; \( p = 0.04 \)).

**Conclusion of the Chapter**
De-escalation strategies with use of platelet function testing seem to be safe.

**CURRENT PLACE OF PLATELET FUNCTION TESTING IN EVERYDAY CLINICAL PRACTICE**

The ischemic risk in ACS patients undergoing PCI is relatively high in clopidogrel treated patients due to its heterogeneous and unpredictable antiplatelet effect (40, 50). With the common use of more potent antiplatelet agents, increased ischemic risk occurs mainly within first months after ACS, whereas bleeding events are proportional to the duration and intensity of antiplatelet treatment (75, 76). Recently, the idea of de-escalation of antiplatelet therapy was investigated and focused on the net clinical benefit and to minimize the bleeding risk (86, 87). The choice of P2Y\(_{12}\) inhibitors offers a chance for individualization of the therapy based on patient characteristics (81, 118). However, the de-escalation trials were powered for minor bleeding events and not for ischemic events. The prolongation studies with P2Y\(_{12}\) receptor inhibitors as the DAPT trial or the PEGASUS-TIMI 54 trial indicated benefit for longer treatment with potent drugs as prasugrel or ticagrelor (119, 120). Therefore, in the era of personalized medicine, according to the latest guidelines on myocardial revascularization, platelet function testing guided P2Y\(_{12}\) inhibitor de-escalation (e.g., switch from newer more potent drug to clopidogrel after an acute phase) may be considered in ACS patients, particularly those unsuitable for 12-month potent antithrombotic therapy due to the increased bleeding risk (class of recommendation IIb, level of evidence B) (12). Such drug de-escalation could be deliberated highly risky without platelet function testing guidance, especially when we take under consideration very high variability in response to P2Y\(_{12}\) receptor inhibitors. In ACS patients undergoing cardiac surgery, platelet function testing is recommended to guide antiplatelet treatment interruption (class of recommendation IIb, level of evidence B), because the preoperative use of P2Y\(_{12}\) inhibitors plus aspirin is associated with increased risk of bleeding and mortality (12, 87).

**CONCLUSIONS**

According to the recent guidelines, platelet function testing use is narrowed to certain clinical scenarios, as P2Y\(_{12}\) inhibitor de-escalation and guidance of antiplatelet treatment interruption in ACS patients undergoing cardiac surgery (12). Due to unfavorable results of previous randomized trials its use is not recommended in everyday clinical practice (12, 87). In the course of modern ACS treatment, as directed in the guidelines, a potent P2Y\(_{12}\) inhibitor, like prasugrel or ticagrelor, are initiated to prevent ischemic complications, but at the same time taking a risk of increased bleeding. When it comes to a major bleed, a switch to a less potent agent is performed, this time risking possible ischemic complications, leading to a vicious circle. The main goal of the precision-based therapy concept is to provide the right drug in the right dose to fit the needs of an individual patient from the very beginning.
of the treatment process (29). The physician’s choice would then be based on clinical, genetic, cellular and environmental variables. All these data would have to be integrated in an algorithm, as previously proposed (28). The gathered clinical information (e.g., based on the PREDICT score), results of platelet function testing and genetic status (CYP2C19 carrier) could be used to personalize antiplatelet therapy in patients with high-thrombotic or bleeding risk. Moreover, the precision-based antiplatelet therapies are also cost-effective, as this would reduce unnecessary hospitalizations due to either ischemic or bleeding complications. Such a test should be simple, fast, not expensive, well-validated, user-friendly, and platelet function testing fits pretty well to this description.

AUTHOR CONTRIBUTIONS

JS-M, MO, and JK contributed conception and design of the manuscript. MO, PA, CE, and AK searched the literature. MO and PA wrote the first draft of the manuscript. JS-M, JK, AK, CE, MP, AT, and CH wrote sections of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

REFERENCES

1. Falk E, Nakano M, Benzton JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists’ view. Eur Heart J. (2013) 34:719–28. doi: 10.1093/eurheartj/ehs411
2. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. (2007) 357:2482–94. doi: 10.1056/NEJMoa071014
3. Siller-Matula JM, Lang IM, Schoergenhofer C, Roest M, Jilma B. Interdependence between osteoprotegerin and active von Willebrand factor in long-term cardiovascular mortality prediction in patients undergoing percutaneous coronary intervention. Thromb Haemost. (2017) 117:1730–8. doi: 10.1160/TH17-02-00087
4. Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol. (2008) 28:403–12. doi: 10.1161/ATVHAHA.107.150474
5. Raju NC, Eikelboom JW, Hirsh J. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med. (2008) 5:766–80. doi: 10.1038/nccardiyo1372
6. Hechler B, Leon C, Vial C, Vigne P, Frelin C, Cazenave JP, et al. The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. Blood. (1998) 92:152–9. doi: 10.1182/blood.V92.1.152.413k27_152_159
7. Jin J, Daniel HJ, Kunapuli SP. Molecular basis for ADP-induced platelet activation: II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem. (1998) 273:2030–4. doi: 10.1074/jbc.273.4.2030
8. Hollopeter G, Jantzen H, Vincent D, Li G, England L, Ramakrishnan V, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. (2001) 409:202–7. doi: 10.1038/35051599
9. Lindemann S, Krämer B, Seizer P, Gawaz M. Platelets, inflammation and atherosclerosis. J Thromb Haemost. (2007) 5:203–11. doi: 10.1111/j.1538-7836.2007.02517.x
10. Awtry EH, Loscalzo J. Aspirin. Circulation. (2000) 101:1206–18. doi: 10.1161/01.CIR.101.12.1206
11. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc. (2005) 293:2126–30. doi: 10.1001/jama.293.17.2126
12. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. (2019) 40:87–165. doi: 10.1093/eurheartj/ehy394
13. Bhatt DL, Mahaffey KW, Fox KA, Gersh BJ, Granger CB, Van Vliet JP, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. (2019). [Epub ahead of print].
14. Winter MP, Schneeweiss T, Cremer R, Biesinger B, Hengstenberg C, Prüller F, et al. Platelet reactivity patterns in patients treated with dual antiplatelet therapy. Eur J Clin Invest. (2019) 49:e13102. doi: 10.1111/eci.13102
15. Ibanez B, Vilahur G, Badimon JJ. Pharmacology of thienopyridines: rationale for dual pathway inhibition. Eur Heart J Suppl. (2006) 8:G3–9. doi: 10.1093/eurheartj/sub047
16. Adamski P, Adamińska U, Ostrowska M, Navarese EP, Kubica J. Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations. Expert Opin Pharmacother. (2018) 19:1415–25. doi: 10.1080/14656566.2018.1510487
17. Siller-Matula JM, Petra A, Delle-Karth G, Huber K, Ay C, Lordkipanidze M, et al. Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: a systematic review and meta-analysis. Eur Heart J Acute Cardiovasc Care. (2017) 6:753–70. doi: 10.1177/2048876116658516
18. Kubisa MJ, Jezewski MP, Gasecka A, Siller-Matula JM, Postula M. Ticagrelor toward more efficient platelet inhibition and beyond. Ther Clin Risk Manag. (2018) 14:129–40. doi: 10.2147/TCRM.S152369
19. Adamski P, Kozinski M, Ostrowska M, Fabiszak T, Navarese EP, Paciorek P, et al. Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thromb Haemost. (2014) 112:224–42. doi: 10.1160/TH13-11-0915
20. Hengstenberg S, Siller-Matula JM. Shedding light on long-term effects of early antiplatelet strategies after fibrinolytic treatment in STEMI. J Am Coll Cardiol. (2019) 73:2829–31. doi: 10.1016/j.jacc.2019.04.008
21. Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, et al. Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - a pooled analysis from the PREFER in AF and PREFER in AF PROLONGATION registries. Int J Cardiol. (2018) 270:160–6. doi: 10.1016/j.ijcard.2018.06.098
22. Schror K, Weber AA. Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thombolyse. (2003) 15:71–80. doi: 10.1023/B:THRO.0000003308.63022.8d
23. Ostrowska M, Adamiński P, Kozinski M, Navarese EP, Fabiszak T, Grzešek G, et al. Off-target effects of glycoprotein IIb/IIIa receptor inhibitors. Cardiol J. (2014) 21:458–64. doi: 10.5030/CJ.a2014.0020
24. Siller-Matula JM, Trenk D, Schror K, Gawaz M, Kristensen SD, Storey RF, et al. EPA (European Platelet Academy). Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv. (2013) 6:1111–28. doi: 10.1016/j.jcin.2013.06.011
25. Siller-Matula JM, Trenk D, Schror K, Gawaz M, Kristensen SD, Storey RF, et al. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors—is an algorithm the answer? Thromb Haemost. (2015) 113:37–52. doi: 10.1160/TH14-03-0238
26. Winter MP, Grove EL, De Caterina R, Gorog DA, Ahrens I, Geisler T, et al. Advocating cardiovascular precision medicine with P2Y12
receptor inhibitors. *Heart J Cardiovasc Pharmacother.* (2017) 3:221–34. doi: 10.1093/hjcp/pww444

30. Tantry US, Bonello L, Aradí D, Price MJ, Jeong YH, Angiolillo DJ, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. *J Am Coll Cardiol.* (2013) 62:2261–73. doi: 10.1016/j.jacc.2013.07.010

31. Aradí D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. *Eur Heart J.* (2015) 36:1762–71. doi: 10.1093/eurheartj/het148

32. Kozinski M, Ostrowska M, Adámki P, Sikora J, Sikora A, Karczmarśka-Wodzka A, et al. Which platelet function test best reflects the in vivo plasma concentrations of ticagrelor and its active metabolite? The HARMONIC study. *Thromb Haemost.* (2016) 116:1140–9. doi: 10.1160/TH16-07-0535

33. Komosa A, Rzymski P, Perek B, Ropacka-Lesiak M, Lesiak M, Siller-Matula JM, et al. Platelets redox balance assessment: Current evidence and methodological considerations. *Vascul Pharmacol.* (2017) 93:95–6. 13. doi: 10.1016/j.vph.2017.06.002

34. Gurbel PA, Bleden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. *Circulation.* (2003) 107:2908–13. doi: 10.1161/01.CIR.0000072771.11429.83

35. Gurbel PA, Bleden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. *J Am Coll Cardiol.* (2005) 45:1392–6. doi: 10.1016/j.jacc.2005.01.030

36. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabaté M, Batuelos C, et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. *Eur Heart J.* (2004) 25:1903–10. doi: 10.1016/j.ehj.2004.07.036

37. Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. *Lancet.* (2015) 386:281–91. doi: 10.1016/S0140-6736(15)60243-4

38. Gurbel PA, Tantry US. Drug insight: clopidogrel nonresponsiveness. *Nat Clin Pract Cardiovasc Med.* (2006) 3:387–95. doi: 10.1038/ncpcardio06062

39. Gurbel PA, Becker RC, Mann KG, Steinshubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. *J Am Coll Cardiol.* (2007) 50:1822–34. doi: 10.1016/j.jacc.2007.07.051

40. Aradí D, Komosić A, Vorošvúc A, Rideg O, Tokés-Füzesi M, Magyarlaki T, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. *Am Heart J.* (2010) 160:534–51. doi: 10.1016/j.ahj.2010.06.004

41. Ait-Mokhtara O, Bonelloa L, Benamarab S, Paganelli F. High on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention. *Thromb Res.* (2016) 138:49–54. doi: 10.1016/j.thromres.2015.12.021

42. Parodi G, Valenti R, Bellandi L, Migliorini A, Marcucci R, Comito V, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. *J Am Coll Cardiol.* (2013) 61:1601–6. doi: 10.1016/j.jacc.2013.03.024

43. Kubica J, Adámks P, Ostrowska M, Sikora J, Kubica JM, Srokà WD, et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. *Heart Lung Circ.* (2015) 24:628–40. doi: 10.2174/1381612824666171213105002

44. Siller-Matula JM, Hintermeier A, Kastner J, Kreiner G, Maurer G, Krotchow C, et al. Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor. *Vascul Pharmacol.* (2016) 79–6. 10. doi: 10.1016/j.vph.2016.01.003

45. Winter MP, Kozinski M, Kubica J, Aradí D, Siller-Matula JM. Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. *Postepy Kardiol Interwencyjne.* (2015) 11:239–50. doi: 10.5114/pki.2015.55596

46. Komosa A, Lesiak M, Krasinski Z, Grygier M, Siniawski A, Skorupski W, et al. Optimal timing of P2Y12 inhibitor loading in patients undergoing PCI: a meta-analysis. *Thromb Haemost.* (2019) 119:1000–20. doi: 10.1055/s-0039-1683421

47. Lemesle G, Schurtz G, Bauters C, Hamon M. High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. *J Thromb Haemost.* (2015) 13:931–42. doi: 10.1111/jth.12907

48. Teng R, Mitchell PD, Butler K. Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals. *Eur J Clin Pharmacol.* (2012) 68:1175–82. doi: 10.1007/s00228-012-1227-4

49. Teng R, Mitchell PD, Butler K. Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers. *J Clin Pharmacol Ther.* (2012) 37:364–8. doi: 10.1111/j.1365-2710.2011.01307.x

50. Varenhorst C, Eriksson N, Johannson Å, Barratt BJ, Hagstroem E, Åkerblom A, et al. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. *Eur Heart J.* (2015) 36:1901–12. doi: 10.1093/eurheartj/het116

51. Kubica J, Kubica A, Jilma B, Adámks P, Hobi EL, Navarese EP, et al. Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. *Int J Cardiol.* (2016) 215:201–8. doi: 10.1016/j.ijcard.2016.04.077

52. Sikora J, Niezgoda P, Baranska M, Buszkow K, Sikinska N, Sroka W, et al. METoclopramide Administration as a Strategy to Overcome MORPHINE-ticagrelor Interaction in PatientS with Unstable Angina PectorIS-The METAMORPHOSIS Trial. *Thromb Haemost.* (2018) 118:2126–33. doi: 10.1055/s-0038-1675605
64. Niegroza P, Sikora J, Baranska M, Sikora A, Buszkó K, Sieminska E, et al. Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetico-pharmacodynamic study. Thorum Haemost. (2017) 117:718–26. doi: 10.1160/TH16-08-0670
65. Adamski P, Sikora J, Laskowska E, Buszkó K, Ostrowska M, Umińska JM, et al. Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. PLoS ONE. (2012) 12:e0186013. doi: 10.1371/journal.pone.0186013
66. Adamski P, Buszkó K, Sikora J, Niegroza P, Fabiszak T, Ostrowska M, et al. Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor. Sci Rep. (2019) 9:3924. doi: 10.1038/s41598-019-04062-0
67. Adamski P, Buszkó K, Sikora J, Baranska M, Ostrowska M, et al. Metabolism of ticagrelor in patients with acute coronary syndromes. Sci Rep. (2018) 8:11746. doi: 10.1038/s41598-018-29619-9
68. Schoergenhofer C, Hohl EL, Schellongowski P, Heinz G, Speidl WS, Siller-Matula JM, et al. Clopidogrel in critically ill patients. Clin Pharmacol Ther. (2018) 103:217–23. doi: 10.1002/cpt.878
69. Umińska JM, Ratajczak J, Buszkó K, Sobczak P, Sroka W, Marszall MP, et al. Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. Cardiol J. (2019). [Epub ahead of print].
70. Eyleten C, Sopińska AM, Pordzik J, Siller-Matula JM, Postula M. Effectiveness of antiplatelet drugs under therapeutic hypothermia: a comprehensive review. Clin Pharmacol Ther. (2019) 106:993–1005. doi: 10.1002/cpt.1492
71. Prüller F, Milke OL, Bis L, Fruhwald F, Frühwald F, Pätzold S, Altmanninger-Pruiller F, Bis L, Milke OL, Fruhwald F, Pätzold S, Altmanninger-Pruiller F, et al. Crushed sublingual versus oral ticagrelor administration strategies in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, active-controlled pharmacodynamic and pharmacokinetic study. Heart Eur Heart J. (2018) 5:139–48. doi: 10.1093/eurheartj/ehy175
72. Cyssu T, Causset S, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. (2016) 388:2015–22. doi: 10.1016/S0140-6736(16)31323-X
73. Aradi D, Tornyos A, Pintér T, Vorobcsuk A, Kónyi A, Faluközy J, et al. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol. (2014) 63:1061–70. doi: 10.1016/j.jacc.2013.12.023
74. Christ G, Siller-Matula JM, Francesconi M, Dechant C, Grohs K, Poddécz-Schweighofer A. Individualising dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomised study. Eur Heart J. (2017) 38:3070–8. doi: 10.1093/eurheartj/ehx175
75. Kubica J, Adamski P, Buszkó K, Baranska M, Sikora J, Marszall MP, et al. Platelet inhibition with standard versus lower maintenance dose of prasugrel early after myocardial infarction (ELECTRA): a randomised, open-label, active-controlled pharmacodynamic and pharmacokinetic study. Heart Eur Heart J. (2017) 390:1747–57. doi: 10.1160/TH16-08-0676
76. Alexopoulos D, Stavrou K, Koniaris I, Gkizas V, Perperis A, Kontoprias K, et al. Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events. Thromb Haemost. (2014) 112:551–7. doi: 10.1160/TH14-02-0119
77. Sibbing D, Steinshlub SR, Schultz S, Schönig A, Kastrati A. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol. (2010) 56:317–8. doi: 10.1016/j.jacc.2010.03.048
78. Kubica J, Adamski P, Buszkó K, Baranska M, Sikora J, Marszall MP, et al. Impact of post-treatment platelet reactivity for occurrence of post-discharge events-European Registry in Atrial Fibrillation). J. Am Heart Assoc. (2017) 6.e005657. doi: 10.1161/JAHA.117.005657
79. Renda G, Pattì G, Lang JM, Siller-Matula JM, Hylek EM, Ambrosio G, et al. Thrombotic and hemorrhagic burden in women: gender-related issues in the response to antiplatebothermic therapies. Int J Cardiol. (2019) 286:198–207. doi: 10.1016/j.jca.2019.02.004
80. Deharo P, Bassez C, Bonnet G, Pankert M, Quilici J, Lambert M, et al. Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparison. Int J Cardiol. (2015) 170:e21–2. doi: 10.1016/j.ijcard.2013.10.043
81. Prüller F, Milke OL, Bis L, Fruhwald F, Pätzold S, Altmanninger-Pruiller F, Bis L, Milke OL, Fruhwald F, Pätzold S, Altmanninger-Pruiller F, et al. Comparison of bioavailability and antiplatelet action of ticagrelor and prasugrel versus ticagrelor in acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. (2017) 390:1747–57. doi: 10.1016/S0140-6736(17)32155-4
82. Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. (2016) 388:2015–22. doi: 10.1016/S0140-6736(16)31323-X
95. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. (2012) 367:2100–9. doi: 10.1056/NEJMoai209979

96. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Srigg D, et al. GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. (2011) 305:1097–105. doi: 10.1001/jama.2011.290

97. Alexopoulos D, Xanthopoulou I, Davlouros P, Plakomyt PE, Panagiotou A, Mavronasios E, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. Am Heart J. (2011) 162:733–9. doi: 10.1016/j.ahj.2011.07.026

98. Alexopoulos D, Panagiotou A, Xanthopoulou I, Komninakis D, Kassissimis G, Davlouros P, et al. Antiplatelet effects of prasugrel vs double clopidogrel in patients on hemodialysis and high on-treatment platelet reactivity. J Thromb Haemost. (2011) 9:2379–85. doi: 10.1111/j.1538-7836.2011.04531.x

99. Capranzano P, Tamburino C, Capodanno D, Micciéhe E, D’Urso L, Calvi V, et al. Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. Thromb Haemost. (2011) 106:1149–57. doi: 10.1160/TH11-05-0346

100. Ferreiro JL, Ueno M, Desai B, Capranzano P, Capodanno D, Angiolillo DJ. Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus. Rev Esp Cardiol. (2011) 64:105–11. doi: 10.1016/j.jrccep.2011.04.008

101. Neubauer H, Kaiser AF, Endres HG, Krüger JC, Engelhardt A, Lask et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with acute myocardial infarction. Am J Cardiol. (2008) 102:524–9. doi: 10.1016/j.amjcard.2008.04.028

102. Neubauer H, Lask S, Engelhardt A, Mügge A. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggreometry-guided therapy modification. Thromb Haemost. (2008) 99:357–62. doi: 10.1160/TH07-10-0624

103. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. (2012) 366:2001–10. doi: 10.1056/NEJMoai209979

104. Trenk D, Hochholzer W, Muller B, Stratz C, Vranckx P, Furgieri A, et al. Antiplatelet response to the 150-mg maintenance dose of clopidogrel in patients with insufficient platelet inhibition after clopidogrel loading for elective coronary stent placement. EuroIntervention. (2008) 4:214–21. doi: 10.4244/EIJV4I2A39

105. Collet JP, Frere C, Quilici J, Morange PE, Moutet JP, Bari L, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. J Am Coll Cardiol. (2008) 52:1349–58. doi: 10.1016/j.jacc.2008.08.018

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Ostrowska, Kubica, Adamski, Kubica, Eyteljen, Postula, Toma, Hingenberg and Siller-Matula. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.